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Background/aim: Intraoperative radiation therapy (IORT) may pose a risk for wound complications. All technical aspects of IORT
regarding early wound complications were evaluated.
Materials and methods: Ninety-three consecutive patients operated on with the same surgical technique and given (study group) or not
given (control group) IORT were included. Wound complications were evaluated in two groups.
Results: Forty-three patients were treated with boost dose IORT and 50 patients were treated with breast-conserving surgery without
IORT. When both groups were compared in terms of early postoperative complications, there were 11 (25.5%) patients with seroma in
the IORT group and 3 patients (6%) in the control group (P = 0.04). While 9 (21%) patients were seen to have surgical site infection (SSI)
in the IORT group, there was 1 (2%) SSI in the control group (P = 0.005). There were 15 (35%) patients with delayed wound healing in
the IORT group and 4 patients (8%) in the control group (P = 0.006).
Conclusion: IORT could have a negative effect on seroma formation, SSI, and delayed healing. It should be kept in mind, however,
that in centers with IORT implementation, the complication rate could also increase. Necessary measures for better sterilization in the
operating room should be taken, while patient wound healing should be monitored closely.
Key words: Breast cancer, intraoperative radiotherapy, wound complications

1. Introduction
With the expansion of regular screening programs,
breast cancer can be detected at an earlier stage in
socioeconomically developed countries (1). Whole breast
irradiation (WBI) followed by an additional dose to the
tumor bed is accepted as the standard approach in early
stage invasive breast cancer treated with breast-conserving
surgery (BCS). An alternative to this treatment is partial
breast irradiation (PBI), but the effects are not clear.
The amount of irradiated breast tissue decreased
and treatment time was shortened with PBI in earlystage breast cancer. With this technique, normal breast
parenchyma and surrounding tissues (e.g., the heart and
lungs) were better preserved, along with better cosmetic
results, given local control rates comparable with whole
breast radiotherapy (2–5). Among PBI methods, interstitial
brachytherapy, mammocyte techniques, intraoperative
radiotherapy (IORT), and three-dimensional conformal/
intensity modulated radiation therapy (IMRT) can also be
considered (6). Among PBI techniques, IORT has been the
* Correspondence: lutfidogan1@yahoo.com

most commonly used and the most popular technique in
recent years.
In IORT, the tumor bed is irradiated under direct
observation during the operation and completed by a
single application with lower doses to surrounding tissue.
In WBI, patients must come to the hospital on a daily
basis for 6–7 weeks. When PBI is conducted with IORT
techniques, treatment time is shortened from 6–7 weeks,
and local treatment is completed with a single application
in well-chosen cases. Thus, patients are offered an
acceptable and easier treatment process in terms of their
social lives. As a result, the cost of treatment is reduced,
with skin toxicity reduced to a minimum as well, along
with better cosmetic results (7,8).
From the surgeon’s view point, this is a new situation
that should be clarified. An open wound is manipulated,
while radiation is delivered in this relatively new technique;
however, this may pose a risk for infective wound
complications. In this study, all technical aspects of IORT
regarding early wound complications were evaluated.
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2. Materials and methods
Ninety-three consecutive patients treated with the same
surgical technique (conventional level I BCS, with up to
20% removal of breast volume and intraglandular flap
mobilization), either given (the study group) or not given
(the control group) IORT between November 2013 and
December 2014 were evaluated retrospectively. Patients in
the study and control groups were given 45–50 Gy WBI
following adjuvant systemic treatments. As the purpose
of this study was to investigate the effects of IORT,
complications in the early period (postoperative first 1
month) were recorded before WBI.
The patients with reexcision or mastectomy due to
positive surgical margins with early follow-up in other
centers, versus those who underwent BCS after neoadjuvant
therapy were excluded. Inclusion of patients in the IORT
program was decided on by a panel of experts in medical
oncology, radiation oncology, surgical oncology, pathology,
radiology, and anesthesiology. Lymphoscintigraphy with
radiocolloid material was performed before surgery for
sentinel lymph node biopsy. Direct axillary dissection was
carried out in patients with clinically positive axilla.
Patients in the study group with the highest risk of local
recurrence were administered a boost dose of IORT to the
tumor bed, using a mobile Mobetron (Intraop Medical
Incorporated, Santa Clara, CA, USA) in the operating
room. Intraglandular flaps were prepared to allow for the
placement of acrylic discs and were sutured temporarily
after acrylic disc placement under the flaps. IORT with a
total boost dose of 10 Gy was applied after the placement
of the appropriate applicator as shown in the Figure. After
completion, the acrylic disc was removed by release of
temporary flap closures, while glandular flaps were sutured
to one another and the muscles. The excision field in all
control group patients was covered with intraglandular
flaps. All patients underwent SLNB and if the SLNB was
negative, no additional intervention to the axilla was
performed. Level 1–2 axillary dissection was performed
for all SLNB-positive patients. A closed suction drain was

placed in the lumpectomy area, while the axillary area was
drained in all patients with axillary node dissection.
Age, radiologic tumor size, pathologic tumor size,
actual tumor size, the distance to skin and pectoral
muscle, flap thickness, hormone receptors and cerbB2
status, hypertension, diabetes, comorbidities such as
heart and lung disease, and smoking (packs/year) were
recorded. Wound complications were evaluated in two
groups, as having minor or major complications. Seroma,
hematoma, surgical site infection (SSI), delayed wound
healing, and incisional wound dehiscence were evaluated
in the minor group. Major serious complications such as
incisional wound dehiscence were evaluated in the major
group. Serous fluid collection, creating patient discomfort
and tension, led to both incision and drainage; they were
considered as seroma. Conversely, collections that caused
hemorrhagic bruises on the skin were considered to be
hematomas. Erythema, purulent discharge, localized
temperature increases, cellulitis, pain, redness, and
tenderness (whether confirmed with wound culture or
not) were considered to be SSI. Simple incision dehiscence
repaired by simple suturing was classified as minor, while
repair of the whole incision in an operating theater was
classified as major wound dehiscence. Wound dehiscence
that heals without intervention was regarded as latewound healing.
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was
used to analyze the data. The differences between the
groups were analyzed with the Mann–Whitney U test, and
the chi-square test was carried out for the comparison of
the complications. P values less than 0.05 were accepted as
statistically significant.
3. Results
The study included 93 early-stage breast cancer patients,
with 43 treated with boost dose IORT and 50 patients
treated with BCS without IORT. Twenty-one patients were
given IORT in the first year of the study (early group)
and 22 patients in the second year (late group). Despite

Figure. Acrylic disc placement under the flaps and application of 10 Gy boost dose.
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the time needed for intraoperative preparation for IORT
in the early group, which took 33 min, this was decreased
to 17 min in the late group. The average time for IORT
application was 2 min. The median age of patients in the
study was 53 (48–67) years. While the median size of
the tumors at radiological examination was 17 (11–27)
mm, it was 20 (12–27) mm at pathological examination.
The average distance of tumors to the skin, areola, and
pectoralis major muscle was measured as 2 cm, 4 cm, and
2 cm, respectively. While the average skin flap thickness
was 1.6 cm, the average specimen weight was 266 ± 83
g. Estrogen receptor (ER) and progesterone receptor
(PR) positivity were confirmed in 79 and 27 patients,
respectively, while cerbB2 was negative in 69 patients. The
grade distribution of patients from grades 1 to 3 was 18, 47,
and 28 patients, respectively. The tumor characteristics of
the two groups are shown in Table 1. When the study and
control groups were compared, there were no significant
differences in age, radiologic tumor size, pathologic tumor
size, distance of tumor to the skin, areola, and pectoral
muscle, flap thickness, weight of the resected specimen,
and tumor characteristics, such as hormone receptors,
grade, and cerbB2.

When both groups were compared for early
postoperative complications; there were 11 (25.5%) patients
with seroma in the IORT group and 3 patients (6%) in the
control group (P = 0.04). While 9 (21%) patients had SSI in
the IORT group, there was 1 (2%) with a SSI in the control
group (P = 0.005). There were 15 (35%) patients with
delayed wound healing in the IORT group and 4 patients
(8%) in the control group (P = 0.006). While 1 patient
had a hematoma in the control group, there were none in
the IORT group. Additionally, while 3 (7%) patients had
minor wound dehiscence in the IORT group, there was
no wound dehiscence in the control group. There was no
statistically significant difference between the groups with
respect to hematoma or minor wound dehiscence, with no
major wound dehiscence in either group (Table 2).
Eleven (25.5%) patients in the study group and 15
(30%) patients in the control group had undergone axillary
dissection. There were 3 patients with diabetes, 9 patients
with hypertension, and 2 patients with COPD in the study
group, while there were 2 patients with diabetes and 10
patients with hypertension in the control group. There
were no smokers in either group. Axillary dissection,
patient and tumor characteristics, and comorbidities had

Table 1. General characteristics of patients.
IORT
(n: 43)

Control group
(n: 50)

P value

Age

51.6 ± 11.8

49.6 ± 10.4

0.4

Radiological tumor size

17.3 ± 5.2

19.06 ± 6.2

0.2

Pathological tumor size

20.3 ± 7.5

22.5 ± 8.4

0.1

Tm distance to pectoral muscle

23.5 ± 7.6

25.7 ± 8.7

0.4

Tm distance to areola

34.2 ± 9.2

40.3 ± 6.9

0.4

Tm distance to skin

20.9 ± 6.6

27.8 ± 9.1

0.3

Flap thickness

15.7 ± 5.1

15.8 ± 0.8

0.1

Length of incision

11.9 ± 2.3

12.1 ± 1.9

0.09

Specimen weight

266.1 ± 93.1

235.5 ± 52.5

0.4

6 (14%)

8 (16%)

0.4

(+)

37 (86%)

42 (84%)

(–)

12 (28%)

16 (32%)

Er
Pr
Cerbb2

Grade

Axillary dissection

(–)

(+)

31 (72%)

34 (68%)

(–)

33 (77%)

36 (72%)

(+)

10 (23%)

14 (28%)

I

8 (18.5%)

10 (20%)

II

21 (49%)

26 (52%)

III

14 (32.5%)

14 (28%)

(+)

11 (25.5%)

15 (30%)

(–)

32 (74.5%)

35 (70%)

0.2
0.3
0.1

0.2
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Table 2. Postoperative complications.
IORT
(n: 43) %
Seroma
SSI
Hematoma
Minor dehiscence
DWH
Major dehiscence

Control group
(n: 50) %

(+)

11

25.5

3

6

(–)

32

74.5

47

94

(+)

9

21

1

2

(–)

34

79

49

98

(+)

0

0

1

2

(–)

43

100

49

98

(+)

3

7

0

0

(–)

40

93

50

100

(+)

15

35

4

8

(–)

28

65

46

92

(+)

0

0

0

0

(–)

43

100

50

100

P value
0.04
0.005
0.2
0.09
0.006
0.5

SSI: Surgical site infection, DWH: Delayed wound healing

no effect on early wound complications. IORT was the
only significant factor on seroma formation (P = 0.03), SSI
(P = 0.02), and delayed wound healing (P = 0.02). Seven
of the 11 patients with a seroma (63%), 7 of the 9 patients
with SSI (78%), and 10 of the 15 patients with delayed
wound healing in the study group (67%) had had surgery
in the first year of the study period.
4. Discussion
Adjuvant radiotherapy after BCS in early-stage breast
cancer is extremely important. When IORT was applied
directly to the tumor bed during surgery, the skin and
subcutaneous tissue were removed from the radiation
field to decrease radiation dose, so that the duration
of treatment was shortened. BCS and external beam
radiotherapy (EBRT), along with an additional dose to the
tumor bed, are standard for treatment of early-stage breast
cancer. In the literature, IORT is a relatively new technique
for wound complications compared with EBRT. Therefore,
the adverse effects were assessed both for late skin toxicity
and cosmetic results. However, our study focused on
early postoperative problems. The TARGIT study was
a prospective, randomized, noninferiority assessment
released in 2010, with patients under 45 who were
undergoing BCS in 28 centers. In that study, 1119 patients
had been randomized to the external beam radiotherapy
arm and 1113 patients to the IORT arm. Rates of hematoma,
seroma, wound dehiscence, and wound infection in the
IORT group were 1%, 2.1%, 2.8%, and 1.8%, respectively.
Rates in the EBRT group were 0.6%, 0.8%, 1.9%, and 1.3%.
Only seroma was found to be higher in the IORT group,
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with a statistically significant difference (2). In that study,
bleeding that required surgical exploration was considered
as hematoma, while collections that required antibiotics
and surgical drainage were defined as wound infections.
Low rates of wound complications in that study might also
be associated with their description. Ruano-Raviana et al.
reviewed 15 studies by comparing the reliability of IORT
and EBRT. In their review, the most common wound
complication, after fibrosis and skin reactions, in the IORT
group was seroma. These complications were much higher
for patients in the EBRT group, although rates ranged
from 3% to 25% (9).
The number of patients in studies focusing on early
wound problems is relatively small. In a study comprising
55 patients, focusing on early complications of IORT from
Australia, the description was similar to that of our own
study, with seroma being reported in 51% of the patients
(10). In an IORT study with 72 patients from China, the
average time for complete healing of a BCS incision was
13–22 days in the IORT arm and 9–14 days in the EBRT
arm (11).
In studies investigating the in vitro effects of IORT,
changes in the cellular phenotype of the surgical wound
and wound fluid, including a change in tissue composition
that weakened the physical connection between cells,
had been expressed. This issue between cells prevents the
introduction of intracellular signaling pathways, to help
initiate wound healing. The novel microenvironment
is considered to be nonideal for the invasion of tumor
cells (12). In other in vitro studies, changes in the
microenvironment caused by IORT in the surgical field
were found to inhibit the activation of hormonal pathways

GÜLÇELİK et al. / Turk J Med Sci
necessary for wound healing: cytokines specifically, as well
as epidermal growth factor, could not be activated (13).
The new microenvironment is not suitable for migration of
cells, which prevents the invasion of possible residual tumor
cells in the surgical field (14). Keratinocyte migration to
the surgical field is required for the epithelialization phase
of wound healing. The production of a new connective
tissue matrix also begins with fibroblast migration. The
distribution of cell migration could similarly disrupt
these phases of wound healing. Radiobiologically, it was
known that the administration of high-dose radiation to
a limited area could lead to vascular damage. The most
important factors adversely affecting wound healing in
surgical practice are reduction of blood flow and hypoxia.
This might explain the high wound complication rate in
patients undergoing IORT.
To discuss the specific factors affecting wound
complication in our series, the time spent in preparation
of IORT should be added to both total operation time and
prolonged operation time, each of which could be a factor.
In the present study, which reflects our first experience
with patients treated with IORT, 33 min was added in the
first year of the study and it was a striking feature. Apart
from this, next to the surgical team, radiation oncologists,
technicians, and physical engineers were included in the
operating room, creating an unusually crowded room.
Another factor might be the possible violation of sterility
rules in the facilitation of the IORT device at the operating
table. As the experience of the team increased with higher
numbers of procedures, operations in the second year
were only prolonged by an average of 17 min. Moreover, as
the number of procedures increased, the number of people

in the operating room became more restricted and sterility
rules were complied with more easily. It is remarkable that
the critical part of wound complications occurred in the
first year of the study.
Factors such as advanced age, obesity, diabetes,
hypertension, anemia, COPD, weight of the specimen,
and smoking have been proposed to affect wound
complication in breast cancer surgery, which includes
aspects of surgical procedures in other studies (15). In
our study, comorbidities of patients did not affect the
complication rate. A possible explanation was thought to
be the small number of patients with comorbid diseases in
each group. Likewise, our series did not have any patients
with a smoking history.
In recent years, IORT as a method for the local treatment
of breast cancer is being used at an increasing rate. Our
hospital is one of the first centers in the country using this
technique. As a result, its impact on local recurrence rates
and wound healing is important for surgeons. This study
reflects our early experience with IORT. We conclude that
IORT might have a negative effect on seroma formation,
SSI, and healing time. As our experience increases, these
adverse effects of IORT might also decrease. Further
studies with increased numbers of patients are needed
from centers in which IORT has been used for longer
periods. It should be kept in mind, however, that in centers
with IORT implementation, the complication rate might
also increase. Necessary measures for better sterilization in
the operating room should be taken, while patient wound
healing should be monitored closely. It is clear that the
adverse effects of IORT on wound complications should
be closely watched.
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